Ascelia Pharma AB

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates Orviglance (former working name Mangoral) and Oncoral in clinical development. Ascelia Pharma has global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). About Orviglance (Mangoral) Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function....

Contrast media,radiology,chronic kidney disease,mri,acute kidney injury,nsf,contrast induced nephropathy,orphan drug,oncology,and drugdevelopment

Ascelia pharma ab operates in the Pharmaceutical manufacturing industry.

Ascelia pharma ab's revenue is 11m - 100m

Ascelia pharma ab has 11 - 50 employees.